Similar articles

• [Neuroendocrine gastric carcinoma. A case report and review of current management].

  Mondragón-Sánchez A, Mondragón-Sánchez R, Bernal Maldonado R, Baquera-Heredia J, Gómez-Gómez E. Mondragón-Sánchez A, et al. Rev Gastroenterol Mex. 2003 Apr-Jun;68(2):129-32. Rev Gastroenterol Mex. 2003. PMID: 15127650 Spanish.
• Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems?

  Scherübl H, Cadiot G, Jensen RT, Rösch T, Stölzel U, Klöppel G. Scherübl H, et al. Endoscopy. 2010 Aug;42(8):664-71. doi: 10.1055/s-0030-1255564. Epub 2010 Jul 28. Endoscopy. 2010. PMID: 20669078 Review.
• Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome.

  D'Adda T, Keller G, Bordi C, Höfler H. D'Adda T, et al. Lab Invest. 1999 Jun;79(6):671-7. Lab Invest. 1999. PMID: 10378509
• [Clinicopathological features and prognosis of different gastric carcinoid subtypes].

  Liang JW, Zhou ZX, Liu Q, Bai XF, Zhao P. Liang JW, et al. Zhonghua Zhong Liu Za Zhi. 2008 Nov;30(11):866-9. Zhonghua Zhong Liu Za Zhi. 2008. PMID: 19173835 Chinese.
• Neuroendocrine tumours.

  Granberg D, Oberg K. Granberg D, et al. Cancer Chemother Biol Response Modif. 2005;22:471-83. Cancer Chemother Biol Response Modif. 2005. PMID: 16110625 Review. No abstract available.